Caffeine is the most widely used psychoactive substance in the world, and its medical visibility in psychiatry is correspondingly low — until a patient lands in the emergency department tachycardic and tremulous, or returns to clinic with a headache they did not have last week. Caffeine intoxication and caffeine withdrawal are formal DSM-5-TR diagnoses, while caffeine use disorder sits in Section III as a condition warranting further study. The pharmacology is unusually clean for psychiatry: caffeine is a competitive adenosine A1 and A2A receptor antagonist, and almost every clinical feature flows from that single mechanism. Two practical points anchor the topic. First, withdrawal is real, predictable, and frequently mistaken for migraine, viral illness, or relapsed depression. Second, the dose-response curve is steep and idiosyncratic — 200 mg ruins one patient's sleep and barely touches another's. The bottom line: ask about caffeine in every workup of anxiety, insomnia, palpitations, or unexplained headache.

Caffeine consumption is near-universal in industrialized populations, which means caffeine-related disorders are common but underdiagnosed. Most clinical attention concentrates on heavy users, adolescents drinking energy drinks, and patients with comorbid anxiety or cardiac disease.

Consumption patterns

• Approximately 85% of adults in the United States consume caffeine daily, with a mean intake near 165-200 mg per day.^[1]
• Coffee accounts for the majority of adult intake; soft drinks and energy drinks dominate adolescent intake.^[1]
• A standard 8-oz brewed coffee contains roughly 95-165 mg of caffeine; an espresso shot 63 mg; a 16-oz energy drink 150-300 mg; a 12-oz cola 30-50 mg.^[1-2]

Prevalence of disorders

• Caffeine withdrawal occurs in roughly 50% of regular daily users who abruptly abstain, with onset within 12-24 hours.^[3]
• Population estimates for caffeine use disorder (DSM-5-TR Section III criteria) range from 8% to 30% of regular consumers, depending on threshold and sample.^[4]
• Caffeine intoxication severe enough to prompt medical contact is rare in coffee-only drinkers and disproportionately reported with energy drinks, caffeine pills, and powdered caffeine.^[5]

Risk factors

• Heavy daily intake (>400 mg/day in adults; >100 mg/day in adolescents) raises the probability of both withdrawal and adverse cardiovascular effects.^[2]
• Genetic variation in CYP1A2 activity (the CYP1A2 gene) and in the adenosine A2A receptor (ADORA2A) influences clearance and subjective response.^[6]
• Comorbid anxiety, panic disorder, bipolar disorder, and primary insomnia amplify caffeine sensitivity.^[7]
• Pregnancy markedly slows caffeine clearance, with third-trimester half-life often 2-3 times non-pregnant values.^[8]

Caffeine's clinical profile follows directly from adenosine antagonism in the central nervous system and periphery. Tolerance and withdrawal reflect upregulation of adenosine signaling during chronic exposure.

Pharmacology

• Caffeine is a competitive antagonist at adenosine A1 and A2A receptors; A2A blockade in the nigrostriatal pathway and striatum disinhibits dopamine release, accounting for its mild reinforcing properties.^[9]
• Oral bioavailability approaches 100%; peak plasma concentration occurs at 30-60 minutes.^[2]
• Hepatic metabolism is dominated by CYP1A2, with a half-life of 3-5 hours in healthy adults, prolonged in pregnancy, liver disease, and with concurrent fluvoxamine or oral contraceptives.^[6,8]
• Smoking induces CYP1A2 and roughly doubles caffeine clearance; abrupt smoking cessation can precipitate caffeine toxicity at previously tolerated doses.^[6]

Neurobiology of tolerance and withdrawal

• Chronic caffeine exposure upregulates adenosine A1 and A2A receptor density, producing tolerance to subjective stimulant effects within days to weeks.^[9]
• Abrupt cessation leaves an unopposed surplus of adenosine signaling, with cerebral vasodilation that correlates with the characteristic withdrawal headache.^[3,9]
• Cross-sensitization with other psychostimulants is modest; caffeine has weaker dopaminergic reinforcement than cocaine or amphetamine, which is why dependence severity is generally mild.^[10]

Peripheral effects

• Caffeine increases catecholamine release, raising heart rate, systolic blood pressure (typically 5-10 mmHg acutely), and lipolysis.^[2]
• Diuresis is modest and tolerance to the diuretic effect develops within days.^[2]
• Lower esophageal sphincter relaxation and increased gastric acid secretion contribute to reflux and dyspepsia.^[2]

DSM-5-TR recognizes three caffeine-related entities: caffeine intoxication, caffeine withdrawal, and other caffeine-induced disorders (anxiety, sleep). Caffeine use disorder appears in Section III as a proposed condition. ICD-11 places these conditions under "Disorders due to use of caffeine" (codes 6C48.x).

Caffeine intoxication (DSM-5-TR; ICD-10-CM F15.920):

• Recent consumption of caffeine, typically >250 mg.^[11]
• Five or more of the following developing during or shortly after use: restlessness, nervousness, excitement, insomnia, flushed face, diuresis, gastrointestinal disturbance, muscle twitching, rambling flow of thought and speech, tachycardia or cardiac arrhythmia, periods of inexhaustibility, psychomotor agitation.^[11]
• Symptoms cause clinically significant distress or functional impairment, are not attributable to another medical condition, and are not better explained by another mental disorder.^[11]

Caffeine withdrawal (DSM-5-TR; ICD-10-CM F15.93):

• Prolonged daily use of caffeine followed by abrupt cessation or reduction.^[11]
• Within 24 hours, three or more of: headache, marked fatigue or drowsiness, dysphoric mood or irritability, difficulty concentrating, flu-like symptoms (nausea, vomiting, muscle pain).^[11]
• Symptoms cause clinically significant distress or functional impairment and are not better explained by another disorder or substance.^[11]

Other caffeine-induced disorders

• Caffeine-induced anxiety disorder — anxiety symptoms developing during or soon after caffeine use, exceeding what intoxication alone would predict.^[11]
• Caffeine-induced sleep disorder — prominent sleep disturbance attributable to caffeine, with insomnia the dominant subtype.^[11]
• Both diagnoses require that symptoms cause distress or impairment and are not better explained by an independent disorder.^[11]

Proposed caffeine use disorder (DSM-5-TR Section III):

• Three core criteria are required for the proposed diagnosis: persistent desire or unsuccessful efforts to cut down, continued use despite knowledge of a physical or psychological problem caused by caffeine, and withdrawal as manifested by the characteristic syndrome.^[11]
• The narrower three-criterion threshold (versus the 2-of-11 threshold used elsewhere in substance use disorders) reflects how commonly mild tolerance and use-despite-knowledge occur in the general population.^[4,11]

ICD-11 differences

• ICD-11 includes "caffeine dependence" (6C48.2) as a formal diagnosis rather than a research category.^[12]
• ICD-11 also codes "harmful pattern of use of caffeine" (6C48.1) without requiring the full dependence syndrome.^[12]

The classic presentations are an over-caffeinated young adult in the emergency department and a Monday-morning withdrawal headache in a coffee-dependent professional who skipped breakfast. Recognition usually hinges on a careful exposure history, including hidden caffeine sources.

Intoxication presentation

• Onset within 15-45 minutes of ingestion; symptom peak at 1-2 hours, paralleling plasma concentration.^[2]
• Sympathomimetic findings predominate: sinus tachycardia, hypertension, hyperreflexia, fine tremor, mydriasis, diaphoresis.^[5]
• Severe intoxication (typically >1 g acutely, or lower in caffeine-naive patients) can produce supraventricular and ventricular arrhythmias, seizures, rhabdomyolysis, hypokalemia, hyperglycemia, and metabolic acidosis.^[5,13]
• Plasma levels above approximately 80-100 mg/L are associated with life-threatening toxicity; fatalities have been reported with powdered caffeine and concentrated liquid caffeine products.^[13]

Withdrawal presentation

• Headache is the cardinal feature, typically bilateral, pulsating, and worsened by exertion; it begins 12-24 hours after the last dose and peaks at 24-48 hours.^[3]
• Associated symptoms include fatigue, drowsiness, depressed mood, irritability, difficulty concentrating, and flu-like complaints; duration is typically 2-9 days.^[3]
• Even moderate habitual intake (as little as 100 mg/day) is sufficient to produce a recognizable withdrawal syndrome in a substantial minority of users.^[3]

Sleep and anxiety features

• Caffeine-induced sleep disorder typically presents as prolonged sleep latency, reduced total sleep time, and reduced slow-wave sleep, with effects persisting up to 6 hours after a late-afternoon dose in slow metabolizers.^[14]
• Caffeine-induced anxiety frequently mimics panic disorder, with palpitations, derealization, and a sense of impending doom; patients with primary panic disorder are particularly sensitive.^[7]

Always ask about energy drinks, pre-workout supplements, and caffeine pills — patients rarely volunteer these as "caffeine."^[5]

Caffeine intoxication and withdrawal mimic common psychiatric and medical conditions, and a missed caffeine history is one of the more embarrassing diagnostic errors in outpatient psychiatry. The differential narrows quickly with timing, dose, and exposure history.

Differentiating intoxication

• Generalized anxiety disorder and panic disorder — sustained worry or recurrent unexpected attacks, present without caffeine exposure; in caffeine-induced anxiety, symptoms remit within hours to days of cessation.^[7,11]
• Stimulant intoxication (cocaine, amphetamine, methamphetamine) — more intense euphoria, paranoia, hyperthermia, and dilated pupils; toxicology screen distinguishes.^[5]
• Hyperthyroidism — tremor, tachycardia, heat intolerance, weight loss; TSH and free T4 differentiate.^[15]
• Pheochromocytoma — paroxysmal hypertension with headache, palpitations, and diaphoresis; suspect when caffeine intake is modest but symptoms are severe.^[15]
• Sympathomimetic toxicity from decongestants, MDMA, synthetic cathinones — overlapping presentation; rely on exposure history.^[5]

Differentiating withdrawal

• Migraine — unilateral, photophobia, phonophobia, often with aura; caffeine withdrawal headache is typically bilateral and not associated with aura.^[3]
• Viral illness — fever and lymphadenopathy support viral etiology; caffeine withdrawal is afebrile.^[3]
• Major depressive episode — depressed mood and anergia persist beyond a week; caffeine withdrawal resolves within 2-9 days of complete abstinence.^[3]
• Opioid withdrawal — yawning, lacrimation, rhinorrhea, piloerection, and dilated pupils favor opioid withdrawal.^[16]

Assessment hinges on a quantitative caffeine history and a focused exam to exclude medical mimics. Most patients are managed in the outpatient setting; severe acute intoxication warrants emergency evaluation.

History elements

• Quantify all sources: coffee, tea, soft drinks, energy drinks, pre-workout supplements, caffeine pills, chocolate, and over-the-counter analgesics containing caffeine.^[1-2]
• Document timing of last dose relative to symptom onset and the temporal relationship of symptom resolution to abstinence or re-exposure.^[3,11]
• Screen for concurrent stimulants, sympathomimetic medications, recent smoking cessation, pregnancy, and CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives).^[6,8]
• Ask explicitly about energy-drink mixing with alcohol, which masks intoxication signs and is associated with risk-taking behavior.^[5]

Physical examination

• Vital signs: heart rate, blood pressure, temperature; look for sinus tachycardia, mild hypertension, and afebrile state.^[5]
• Cardiovascular exam for arrhythmia; neurologic exam for tremor, hyperreflexia, and clonus.^[5]
• Mental status for restlessness, pressured speech, and circumstantial thought.^[11]

Rating scales and instruments

• The Caffeine Consumption Questionnaire-Revised quantifies daily intake across sources and is the most widely used research instrument.^[17]
• The Caffeine Withdrawal Symptom Questionnaire rates severity across 23 items and is useful for tracking taper progress.^[18]
• For anxiety comorbidity, the GAD-7 and Hamilton Anxiety Rating Scale support measurement-based care; for insomnia, the Insomnia Severity Index.^[19]

Laboratory and imaging

• In suspected severe intoxication, obtain electrolytes (hypokalemia is common), glucose, creatine kinase, ECG, and a serum caffeine level when available.^[13]
• TSH and free T4 to exclude hyperthyroidism in patients with persistent symptoms despite caffeine cessation.^[15]
• Toxicology screen when stimulant co-use is suspected.^[5]
• Routine neuroimaging is not indicated unless focal neurologic findings or atypical headache features are present.^[3]

Treatment is largely supportive and behavioral. There are no FDA-approved pharmacotherapies for caffeine use disorder, withdrawal, or intoxication; management focuses on graded dose reduction, symptom relief, and addressing comorbid sleep and anxiety disorders.

General principles

• Establish baseline daily caffeine intake quantitatively before recommending change.^[2]
• Match the intervention to severity: brief advice and self-monitoring for mild problematic use; structured taper and cognitive-behavioral approaches for moderate-to-severe presentations.^[20]
• Treat comorbid anxiety, insomnia, and mood disorders concurrently — caffeine cessation alone rarely resolves an independent anxiety disorder.^[7]

Caffeine intoxication

• Mild-to-moderate intoxication: reassurance, oral hydration, and a quiet environment; symptoms resolve as plasma levels fall over 3-6 hours.^[13]
• Moderate-to-severe presentations (chest pain, arrhythmia, seizure, hypokalemia): continuous cardiac monitoring, IV fluids, electrolyte repletion, and benzodiazepines for agitation or seizure.^[13]
• Beta-blockade (esmolol or metoprolol) for supraventricular tachyarrhythmia or hypertensive urgency in severe toxicity; avoid pure beta-blockers when concurrent cocaine or amphetamine use is suspected.^[13]
• Activated charcoal within 1-2 hours of ingestion for large oral overdoses; hemodialysis for life-threatening toxicity with caffeine levels >80-100 mg/L or refractory arrhythmia.^[13]

Caffeine withdrawal

• For elective discontinuation, taper by 10-25% of the daily dose every 2-3 days to minimize headache and fatigue.^[3,20]
• For unplanned withdrawal (perioperative, hospitalization), simple analgesics (acetaminophen, ibuprofen) for headache and resumption of a small caffeine dose (50-100 mg) when clinically permissible.^[3]
• Educate patients that symptoms peak at 24-48 hours and resolve within 2-9 days even without re-dosing.^[3]

Caffeine use disorder (problematic use)

• Brief behavioral intervention with quantitative self-monitoring, goal-setting, and stimulus control (e.g., switching to decaffeinated coffee in the afternoon) reduces intake by 50-75% over 4-6 weeks in motivated patients.^[20]
• Manualized cognitive-behavioral therapy adapted from tobacco cessation programs improves abstinence rates at 6 months versus brief advice alone.^[20]
• Motivational interviewing is appropriate for ambivalent patients, particularly those reluctant to give up perceived performance benefits.^[20]

Caffeine-induced anxiety disorder

• First-line: complete caffeine cessation, with reassessment at 4-6 weeks.^[7]
• If anxiety persists after sustained abstinence, treat as primary anxiety disorder with SSRI or CBT per standard guidelines.^[7]

Caffeine-induced sleep disorder

• First-line: eliminate caffeine after noon, or 8-10 hours before bedtime in slow metabolizers.^[14]
• Add cognitive-behavioral therapy for insomnia (CBT-I) when sleep disturbance persists despite caffeine adjustment.^[19]

The evidence base for caffeine-related disorders draws on controlled human laboratory studies, observational cohorts, and a smaller body of clinical trials of taper and behavioral interventions. The strongest evidence supports the existence of a reliable withdrawal syndrome; evidence for caffeine use disorder as a discrete clinical entity is moderate and contested.

Withdrawal syndrome (high certainty)

• A systematic review of 57 experimental and 9 survey studies established withdrawal as a valid, reliable syndrome occurring across diverse populations and dose levels.^[3]
• Double-blind crossover trials consistently reproduce the syndrome with placebo substitution, with effect sizes for headache and fatigue exceeding 1.0 standard deviation.^[3]
• EVIDENCE_CERTAINTY[withdrawal_syndrome]: high — reproduced across multiple double-blind trials with consistent effect size.^[3]

Intoxication syndrome (high certainty)

• Dose-response studies in caffeine-naive adults reliably reproduce the DSM-5-TR symptom cluster at doses of 250-500 mg, with high inter-rater reliability of clinical diagnosis.^[11]
• Case series of severe intoxication and fatal overdose document a consistent toxidrome at supratherapeutic doses.^[5,13]
• EVIDENCE_CERTAINTY[intoxication]: high — convergent experimental and clinical evidence.

Caffeine use disorder (moderate, contested certainty)

• Cross-sectional surveys using DSM-5-TR Section III criteria identify a 7-9% prevalence among regular adult users.^[4]
• Critics argue the construct medicalizes normative behavior; proponents cite functional impairment and use-despite-harm in a clinically meaningful subgroup.^[4,20]
• EVIDENCE_CERTAINTY[use_disorder_validity]: moderate — construct validity demonstrated in survey samples, but clinical utility and treatment-responsiveness less well established.

Behavioral treatment (moderate certainty)

• A randomized trial of manualized behavioral treatment versus brief advice demonstrated significantly greater reductions in caffeine intake at 6 and 12 months, with a meaningful subset achieving sustained low-level use or abstinence.^[20]
• EVIDENCE_CERTAINTY[behavioral_taper]: moderate — single high-quality RCT plus consistent observational data.

Pharmacotherapy (low certainty)

• No medications have been studied in adequately powered RCTs for caffeine use disorder or withdrawal.^[20]
• EVIDENCE_CERTAINTY[pharmacotherapy]: low — no controlled trials.

Cardiovascular risk in habitual users (low-to-moderate certainty):

• Meta-analyses of cohort studies show no overall increase in cardiovascular mortality at habitual intakes of 200-400 mg/day; a U-shaped relationship with all-cause mortality is described, with lowest risk at 3-4 cups/day of coffee.^[21]
• High-dose energy drink consumption has been associated with arrhythmia and sudden cardiac events in case series and pharmacovigilance reports; randomized evidence is limited.^[5,21]
• EVIDENCE_CERTAINTY[cardiovascular_safety_moderate_use]: moderate — large cohort data; residual confounding likely.
• EVIDENCE_CERTAINTY[energy_drink_arrhythmia]: low — predominantly case-series evidence.

Caffeine is generally well tolerated at habitual moderate doses. Harms cluster at the extremes of acute high-dose exposure, in vulnerable populations, and in interaction with other substances and medications.

Acute harms

• Acute intoxication: cardiac arrhythmia, seizure, hypokalemia, rhabdomyolysis, and rarely death; reported with caffeine pills, powdered caffeine, and concentrated energy products.^[5,13]
• Energy-drink co-ingestion with alcohol: increased risk-taking, masked intoxication, and higher rates of motor-vehicle injury reported in observational studies.^[5]
• Caffeine-induced psychosis: rare; case reports describe transient paranoia and hallucinations at very high doses (>1 g/day chronically).^[22]

Chronic harms

• Sleep disturbance and insomnia, particularly with late-day dosing in slow metabolizers.^[14]
• Worsening of underlying anxiety disorder, panic disorder, and bipolar disorder in susceptible patients.^[7]
• Bone health: high intake (>400 mg/day) has been associated with modestly reduced bone mineral density in some cohort studies; clinical significance is uncertain.^[23]
• Pregnancy: doses >200 mg/day associated with increased risk of fetal growth restriction and pregnancy loss in observational data; causality not fully established.^[8]

Drug interactions

• CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, oral contraceptives, cimetidine) — increase caffeine plasma levels and may precipitate intoxication at habitual doses.^[6,8]
• Lithium — caffeine increases renal clearance; abrupt cessation can elevate lithium levels into the toxic range.^[24]
• Clozapine — co-metabolism via CYP1A2; caffeine cessation may increase clozapine levels.^[24]
• MAOIs and stimulants — additive sympathomimetic effects; counsel moderation.^[24]

Caffeine pharmacokinetics, vulnerability, and management considerations vary substantially across populations. Pregnancy, childhood and adolescence, advanced age, and serious mental illness each warrant tailored counseling.

Pregnancy and lactation

• Caffeine half-life lengthens from ~5 hours in the non-pregnant state to roughly 7-10 hours by the second trimester and 10-15 hours by the third trimester, reflecting reduced CYP1A2 activity.^[8]
• Major obstetric guidelines recommend limiting intake to <200 mg/day during pregnancy.^[8]
• Approximately 1% of maternal caffeine appears in breast milk; infant exposure can produce irritability and poor sleep, especially in neonates with immature CYP1A2 metabolism.^[8]

Children and adolescents

• The American Academy of Pediatrics has discouraged routine caffeine and energy-drink consumption in children and adolescents, citing insufficient safety evidence and the potential for cardiovascular, sleep, and behavioral effects.^[25]
• Energy drink consumption in adolescents has been associated with sleep disturbance, anxiety, and rare cardiac events; pediatricians should screen explicitly.^[25]

Older adults

• Reduced hepatic blood flow modestly prolongs caffeine half-life; baseline tachycardia and insomnia may be more prominent.^[26]
• Polypharmacy increases interaction risk, particularly with CYP1A2 substrates and inhibitors.^[26]

Patients with serious mental illness

• Caffeine use is highly prevalent in inpatient psychiatric settings, often exceeding 700 mg/day.^[27]
• Heavy caffeine use in schizophrenia and bipolar disorder is associated with increased agitation, sleep disruption, and clozapine level fluctuation.^[24,27]
• Pragmatic guidance: cap inpatient caffeine availability, screen daily intake on admission, and incorporate caffeine reduction into recovery planning.^[27]

Athletes and performance users

• Caffeine is no longer prohibited by the World Anti-Doping Agency (WADA) but remains on its monitoring program; doses of 3-6 mg/kg pre-exercise reliably improve endurance and short-duration high-intensity performance.^[28]
• Counseling should address dependence, withdrawal during off-season, and risk of intoxication with stacked stimulants (caffeine, beta-agonists, ephedra-containing products).^[28]

Prognosis for caffeine-related disorders is favorable when patients accept reduction and address comorbid conditions. Most withdrawal syndromes resolve within 9 days; behavioral interventions for caffeine use disorder show sustained benefit at 6-12 months.

• Caffeine intoxication: complete resolution within 24 hours of cessation in mild-to-moderate cases; mortality in severe intoxication is approximately 1-2% in published case series, predominantly from arrhythmia and seizure.^[13]
• Caffeine withdrawal: symptoms peak at 24-48 hours and resolve by day 9 in nearly all patients; headache is the slowest to remit.^[3]
• Caffeine use disorder: in the absence of treatment, the natural course is chronic and relapsing; with structured behavioral treatment, a substantial proportion achieve clinically meaningful reduction at 6-12 months, though precise abstinence rates vary across trials.^[20]
• Caffeine-induced anxiety disorder: typically remits within 1-4 weeks of complete abstinence; persistence beyond 6 weeks suggests an independent primary anxiety disorder.^[7]

Acute severe caffeine intoxication is a medical emergency. Suspect when ingestion exceeds 1 g acutely or when caffeine pills or powdered/concentrated products are involved.

Initial assessment

• ABCs and continuous cardiac monitoring; obtain 12-lead ECG.^[13]
• Establish IV access; draw electrolytes, glucose, magnesium, creatine kinase, troponin, and serum caffeine level when available.^[13]
• Quantify exposure: product, dose, time of ingestion, co-ingestants (especially alcohol, stimulants, and sympathomimetics).^[5]

Stabilization

• IV normal saline for volume resuscitation; aggressive potassium and magnesium repletion (hypokalemia is common and worsens arrhythmia).^[13]
• Benzodiazepines (IV lorazepam or midazolam) for agitation, seizures, and sympathomimetic symptoms.^[13]
• Short-acting beta-blocker (esmolol) for supraventricular tachycardia or unstable hypertension when stimulant co-use is excluded.^[13]
• Activated charcoal 1 g/kg within 1-2 hours of large oral ingestion if airway is protected.^[13]
• Hemodialysis for severe toxicity refractory to supportive care, caffeine level >80-100 mg/L, refractory arrhythmia, or seizures.^[13]

Disposition

• Mild intoxication: discharge after symptom resolution and brief counseling.
• Moderate to severe intoxication: admit to monitored bed or ICU; psychiatric consultation for intentional overdose.

Several aspects of the caffeine-related disorders framework remain contested. Clinicians should be aware of the active debates that shape clinical practice and patient counseling.

Status of caffeine use disorder as a diagnosis:

• DSM-5-TR retains caffeine use disorder in Section III pending further validation; ICD-11 includes caffeine dependence as a formal diagnosis.^[4,11-12]
• The diagnostic asymmetry reflects unresolved questions about clinical utility, treatment-responsiveness, and the boundary between heavy normative use and disorder.^[4]

Cardiovascular safety of habitual moderate use

• Large prospective cohorts suggest a neutral or favorable cardiovascular profile for habitual moderate coffee consumption (3-4 cups/day).^[21]
• Critics note residual confounding, healthy-user bias, and uncertainty about whether findings generalize to non-coffee caffeine sources (energy drinks, supplements).^[21]

Energy drinks and arrhythmia

• Case reports and pharmacovigilance data raise concern for arrhythmia, particularly in adolescents and patients with underlying long-QT syndromes; randomized data are limited.^[5]
• Industry-funded studies tend to report null findings; independent observational data tend to report adverse signals.^[5]

Pregnancy thresholds

• Major obstetric guidelines converge on <200 mg/day, but observational studies suggest dose-response effects below that threshold; whether a safe lower bound exists is uncertain.^[8]

Caffeine as performance enhancement

• Removal from the WADA prohibited list reflects evidence that habitual use is widespread and difficult to police; some argue this normalizes dependence in elite athletes.^[28]

• Withdrawal occurs after as little as 100 mg/day of habitual intake; expect headache, fatigue, dysphoria starting 12-24 hours after cessation and peaking at 24-48 hours.^[3]
• DSM-5-TR caffeine intoxication requires recent use plus 5 of 12 symptoms with significant distress or impairment.^[11]
• DSM-5-TR places caffeine use disorder in Section III (research criteria), requiring 3 specified criteria; ICD-11 codes caffeine dependence as a formal diagnosis.^[4,11-12]
• CYP1A2 polymorphisms produce 40-fold variation in caffeine clearance; slow metabolizers tolerate poorly and experience prolonged sleep effects.^[6]
• Pregnancy progressively prolongs caffeine half-life across trimesters, often to 2-3 times non-pregnant values by the third trimester; counsel <200 mg/day.^[8]
• Caffeine doses >1 g acutely can produce severe toxicity; serum levels >80-100 mg/L predict life-threatening events.^[13]
• Behavioral taper (10-25% every 2-3 days) minimizes withdrawal during elective cessation; CBT-based interventions outperform brief advice at 6 months.^[20]
• Always screen for hidden caffeine sources — energy drinks, pre-workout supplements, OTC analgesics, caffeine pills — when evaluating anxiety, palpitations, or insomnia.^[5]
• Fluvoxamine, ciprofloxacin, and oral contraceptives raise caffeine plasma levels; reduce intake by 50% when starting these agents.^[6,8]
• Caffeine cessation in patients on clozapine or lithium can produce clinically significant level changes; coordinate with prescribing psychiatrist.^[24]

This article was prepared as an educational summary. The author reports no relevant financial relationships. No funding from caffeine or beverage industry sources was received. All recommendations reflect peer-reviewed evidence and major clinical guidelines available through the literature search date noted above.